Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astellas Pharma Inc (ALPMY)

Astellas Pharma Inc (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Astellas Pharma Inc 2-5-1 Nihonbashi-Honcho Chuo-Ku Tokyo M0 103-8411 JPN

www.astellas.com Employees: 14,754 P: 813-3244-3000

Description:

Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan.

Key Statistics

Overview:

Market Capitalization, $K 18,223,304
Enterprise Value, $K 22,093,304
Shares Outstanding, K 1,809,663
Annual Sales, $ 10,620 M
Annual Net Income, $ 113,000 K
Last Quarter Sales, $ 3,108 M
Last Quarter Net Income, $ 241,340 K
EBIT, $ 548,150 K
EBITDA, $ 1,869 M
60-Month Beta 0.36
% of Institutional Shareholders 0.00%
Float, K 1,809,663
% Float 100.00%
Short Volume Ratio 0.06

Growth:

1-Year Return -16.63%
3-Year Return -38.33%
5-Year Return -40.80%
5-Year Revenue Growth -9.76%
5-Year Earnings Growth -44.23%
5-Year Dividend Growth 10.34%

Per-Share Information:

Most Recent Earnings 0.13 on 10/30/24
Next Earnings Date 11/06/24
Earnings Per Share ttm 0.60
EPS Growth vs. Prev Qtr -45.83%
EPS Growth vs. Prev Year 1,400.00%
Annual Dividend Rate, $ 0.15
Annual Dividend Yield 1.51%
Most Recent Dividend 0.152 on 03/26/24
Next Ex-Dividends Date 03/26/24
Dividend Payable Date 12/18/14
Dividend Payout Ratio 25.27%
Most Recent Split 5-4 on 04/02/14

ALPMY Ratios

Ratio
Price/Earnings ttm 16.78
Price/Earnings forward 16.33
Price/Earnings to Growth N/A
Return-on-Equity % 10.33%
Return-on-Assets % 4.62%
Profit Margin % 1.06%
Debt/Equity 0.59
Price/Sales 1.64
Price/Cash Flow 8.72
Price/Book 1.70
Book Value/Share 5.93
Interest Coverage 3.06

ALPMY Dividends

Date Value
03/26/24 $0.1520
09/27/23 $0.1680
03/29/23 $0.1530
09/29/22 $0.1560
03/28/22 $0.1370
09/27/21 $0.1560
03/29/21 $0.1360
09/25/20 $0.1430
03/26/20 $0.1360
09/25/19 $0.1570
09/26/18 $0.1670
03/29/18 $0.1170
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar